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Abstract 
Background: Soft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues. Gastrointestinal stromal 
tumour (GIST) is the commonest STS and arises within the wall of the gastrointestinal (GI) tract. While most GISTs 
occur in the stomach they do occur in all parts of the GI tract. As with other STS, it is important that GISTs are man-
aged by expert teams, to ensure consistent and optimal treatment, as well as recruitment to clinical trials, and the 
ongoing accumulation of further knowledge of the disease. The development of appropriate guidance, by an expe-
rienced panel referring to the evidence available, is therefore a useful foundation on which to build progress in the 
field.
Methodology: British Sarcoma Group guidelines for the management of GIST were initially developed by a panel of 
physicians experienced in the management of GIST. This current version has been updated and amended with refer-
ence to other European and US guidance. We have received input from representatives of all diagnostic and treat-
ment disciplines as well as patient representatives.  Levels of evidence and strength of recommendation gradings are 
those used by ESMO adapted from those published by the Infectious Disease Society of America.
Conclusions: The guidelines cover aetiology, genetics and underlying molecular mechanisms, diagnosis and 
initial investigations, staging and risk stratification, surgery, neoadjuvant and adjuvant therapy, the management of 
advanced disease and follow-up. The importance of mutational analysis in guiding treatment is highlighted, since this 
can indicate the most effective treatment and avoid administration of ineffective drugs, emphasising the need for 
management in specialist centres.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
British Sarcoma Group guidelines for the management 
of GIST were initially developed in 2004 by a panel of 
physicians experienced in the management of GIST rep-
resenting all diagnostic and treatment disciplines. These 
Clinical Practice Guidelines update reflect the improve-
ments in our knowledge of the disease and developments 
that have taken place since then [1]. Levels of evidence 
and strength of recommendation gradings are those used 
by ESMO adapted from those published by the Infectious 
Disease Society of America (Table 1) [2].
Incidence
Gastrointestinal stromal tumours (GISTs) are rare 
cancers, with an estimated unadjusted incidence of 
1.5/100,000/year [3]. Data from the Rhȏne-Alpes region 
of France [4] and “NHS England Cancer Registry” (per-
sonal communication) suggest an incidence of just under 
11 per million per annum, equating to 650 clinically 
meaningful new cases a year in the UK, approximately 
900 in total. Accurate data on prevalence in the UK are 
not yet available.
The median age at diagnosis is around 60–65  years, 
with a wide range. Occurrence in children, adolescents 
and younger patients is very rare, although paediatric 
GISTs represent a distinct subset, marked by female pre-
dominance, absence of KIT/platelet-derived growth fac-
tor alpha (PDGFRA) mutations, usually gastric origin, 
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often multifocal, and with possible lymph node metasta-
ses [5].
Aetiology
In most cases the aetiology is unknown, although it is 
reported that patients with GIST are more likely to be 
diagnosed with another cancer than the general popu-
lation [6, 7], suggesting a likely link with inherited 
increased susceptibility to cancer in some patients. In 
the majority of cases GIST is associated with an acti-
vating mutation in either the KIT or PDGFRA (platelet 
derived growth factor receptor alpha) gene. However, 
other rare drivers may include mutations in NF1 (neu-
rofibromatosis type 1, loss of function) or BRAF (gain 
of function). Tumours lacking mutations in KIT or 
PDGFRA are often called “wild-type”, and those lack-
ing mutations in not only these genes but also BRAF 
and NF1 have been dubbed “quadruple wild-type” [8]. 
Specific advice concerning the management of patients 
with paediatric, “wild-type” and syndromic GIST can 
be obtained from a UK based alliance of medical spe-
cialists via the web site http://www.pawsgistclinic.org.
uk.
A number of genetic syndromes are linked to GIST:
  • The Carney triad syndrome, comprising gastric GIST, 
paraganglioma and pulmonary chondroma (these 
may occur at different ages) [9].
  • Carney–Stratakis syndrome, marked by germ-line 
mutations of one of the SDH subunits A, B, C or D, 
leading to a dyad of GIST and paraganglioma [10, 
11].
  • Type-1 neurofibromatosis, i.e. associated with loss of 
function of NF1, whether sporadic or inherited, and 
absence of mutations in KIT or PDGFRA, the GISTs 
are often multifocal, predominantly located in the 
small bowel [12].
  • Familial GIST, i.e. families with a germ-line autoso-
mal dominant mutation of KIT, are extremely rare, 
presenting with multiple GISTs at an early age.
Diagnosis
Clinical presentation and investigation
The most common symptoms of GIST include upper gas-
trointestinal bleeding and anaemia, whilst larger tumours 
may present with abdominal pain/discomfort and a pal-
pable mass. Small bowel GISTs may remain silent for a 
long period before presenting with an acute event such 
as haemorrhage or rupture. Symptomatic colorectal 
GISTs may present with abdominal pain, obstruction 
and lower gastrointestinal bleeding; oesophageal and 
gastro-oesophageal junction GISTs with dysphagia. Some 
patients may have non-specific systemic symptoms such 
as weight loss, night sweats and fever. Lack of awareness 
of the presenting features may lead to delayed diagnosis 
of GIST in some patients. Small GISTs may be asympto-
matic and are often diagnosed incidentally during inves-
tigation for other conditions.
Small lesions below 2 cm in diameter may safely be fol-
lowed by endoscopic ultrasound on an annual basis and 
biopsied or excised if they continue to grow. For larger 
lesions it is necessary to make a histological diagnosis. The 
standard approach for small nodules of 2 cm or above is 
excisional biopsy, as GISTs of this size carry a higher risk. 
For gastric lesions it is preferable to perform a fine nee-
dle aspirate or core needle biopsy under endoscopic ultra-
sound (EUS) guidance. If this is not feasible, and limited 
surgery is possible, primary resection may be appropriate. 
However, the differential diagnosis of intra-abdominal 
tumours may include leiomyosarcoma, germ cell tumour, 
lymphoma, benign and malignant neurogenic tumours, 
and fibromatosis. Given that the management of these 
conditions differs substantially, and primary excision is 
not always appropriate, it is sometimes necessary to do 
a percutaneous core needle biopsy to confirm the diag-
nosis. This however carries a very small risk of contami-
nating the peritoneal cavity, especially if bleeding were to 
occur. If surgery would require multi visceral resection, or 
is likely to be morbid, e.g. total gastrectomy, then multiple 
core needle biopsies are definitely required, again ideally 
under EUS guidance, or alternatively using an ultrasound/
computed tomography (CT)-guided percutaneous 
approach. Depending on the histological diagnosis initial 
Table 1 Levels of evidence and Grades of recommendation
Levels of evidence
 I Evidence from at least one large randomised, controlled trial of good 
methodological quality (low potential for a bias) or meta-analyses of 
well-conducted randomised trials without heterogeneity
 II Small randomised trials or large randomised trials with a suspicion of 
bias (lower methodological quality) or meta-analyses of such trials or 
of trials with demonstrated heterogeneity
 III Prospective cohort studies
 IV Retrospective cohort studies or case–control studies
 V Studies without control group, case reports, and experts’ opinions
Grades of recommendation
 A Strong evidence for efficacy with a substantial clinical benefit, 
strongly recommended
 B Strong or moderate evidence for efficacy but with a limited clinical 
benefit, generally recommended
 C Insufficient evidence for efficacy or benefit does not outweigh the 
risk or the disadvantages (adverse events, costs,…), optional
 D Moderate evidence against efficacy or for adverse outcome, generally 
not recommended
 E Strong evidence against efficacy or for adverse outcome, never 
recommended
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treatment may be with systemic therapy, e.g., lymphomas, 
mesenteric fibromatosis, germ cell tumours and GIST, or 
alternatively surveillance for benign entities such as non-
malignant neurogenic tumours. Lesions at risk of rupture, 
such as cystic masses, should only be biopsied in special-
ised centres. If a patient presents with obvious metastatic 
disease, then a biopsy of an easily accessible metastatic 
focus should be performed and a laparotomy for diagnos-
tic purposes is usually unnecessary.
Pathologically, the diagnosis of GIST relies on morpho-
logical assessment and immunohistochemistry, the diag-
nosis being supported by CD117 immunopositivity [13, 
14]. More recently DOG1 has been added to the diagnostic 
armamentarium [15, 16]. About 5% of GISTs are CD117 
immunonegative, about 5% of GISTs are DOG1 immu-
nonegative and about 1% of GISTs are immunonegative for 
both. The mitotic count has prognostic value and although 
several risk assessment tools use an index of mitoses per 
50 high-power fields, it would be more accurate and repro-
ducible to express this as the number of mitoses in a total 
area of 5 mm2, which is therefore recommended. If there 
is some diagnostic doubt, particularly in CD117 and/or 
DOG1 immunonegative suspected GIST, molecular analy-
sis for activating mutations in KIT or PDGFRA may help 
confirm the diagnosis. Mutational analysis has predictive 
value for sensitivity to molecular-targeted therapy, and 
also prognostic value. If initial treatment is with imatinib, 
mutational analysis is particularly critical, since some 
GISTs are insensitive to the drug (e.g. PDGFRA exon 18 
mutation D842V). The inclusion of mutational analysis in 
the diagnostic work-up of all GISTs should be considered 
standard practice, with the possible exclusion of sub 2 cm 
non-rectal GISTs, which are very unlikely ever to need 
medical treatment. It is strongly recommended that muta-
tional analysis is performed in centralised laboratories 
which are enrolled in an external quality assurance pro-
gram, and which have expertise in GIST analysis. In KIT/
PDGFRA mutation negative, or “Wild-Type” GIST, immu-
nohistochemistry for succinate dehydrogenase B (SDHB), 
and, if negative, SDHA, should be performed if available, 
since loss of expression may assist the diagnosis and may 
help to guide therapy. In the absence of mutations in KIT 
or PDGFRA it is also important to look for mutations in 
BRAF, a rare, but important finding from a treatment 
perspective, since BRAF inhibitors are available, and also 
in NF1. Patients with neurofibromatosis, who have a ger-
mline mutation in NF1, are at increased risk of GIST and 
this finding may indicate occult neurofibromatosis. The 
optimal treatment for advanced GIST with NF1 mutation 
has yet to be determined. Collection of fresh/frozen tissue 
is encouraged, because new molecular pathology assess-
ments can then be made at a later stage in the patient’s 
interest. Informed consent for tumour banking should be 
sought, so that the tissue is available for later analyses and 
research, provided that local ethical approval is in place. 
Consent forms for the National GIST Tissue Bank based at 
the Royal Marsden Hospital can be found at http://www.
givemysample.org/gist.
Key recommendations:
1. Lesions larger than 2  cm in diameter need to be 
investigated and a diagnosis made. Often this can be 
done by endoscopic ultrasound and needle biopsy, 
particularly if the lesion is in the stomach.
2. The diagnosis should be made by a pathologist expe-
rienced in the disease and include the use of immu-
nohistochemistry and mutational analysis, which 
should be performed by an accredited laboratory.
3. If neoadjuvant treatment with imatinib is planned, it 
is vital to confirm the diagnosis, since there is a wide 
differential. It may be necessary to perform a percu-
taneous core needle biopsy if the tumour is inacces-
sible to endoscopic ultrasound-guided biopsy. Muta-
tional analysis is obligatory, since some GISTs are 
insensitive to imatinib (e.g. those with D842V muta-
tion in exon 18 of PDGFRA).
Risk assessment for primary tumours with no 
evidence of metastatic disease
The TNM classification for staging has several limitations 
and its use is not recommended in this disease. Prognos-
tic factors of proven value are the mitotic rate, tumour 
size, tumour site, and presence or absence of tumour 
rupture. Gastric GISTs have a better prognosis than small 
bowel or rectal GISTs. Tumour rupture through a sero-
sal surface is an adverse prognostic factor and should be 
recorded, whether it took place before or during surgery. 
Mutational status has not been incorporated in any risk 
classification so far, although some genotypes have a dis-
tinct natural history, for example KIT/PDGFRA wild type 
GISTs tend to exhibit more indolent behaviour than KIT 
exon 11 mutant disease.
It is possible to assess risk of recurrence after resection 
of a localised GIST. This can be especially useful in decid-
ing the role of adjuvant therapy in individual patients. 
Several risk classifications have been proposed. An ini-
tial risk classification developed at a consensus meeting 
convened by the National Institute of Health (NIH) [13] 
was useful but only considered size and mitotic index. 
Although the ‘high-risk’ category based on the NIH cri-
teria has a much worse prognosis than the others, with 
both ‘very low-risk’ and ‘low-risk’ categories having a 
very favourable prognosis, the ‘intermediate-risk’ cat-
egory did not reliably identify patients with an unfavour-
able prognosis. A risk classification was proposed by the 
Armed Forces Institute of Pathology, which incorporates 
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the primary tumour site, in addition to mitotic count 
and tumour size, i.e. three of the main prognostic fac-
tors in localized GISTs [17]. There are also problems 
with the application of this risk classification tool since 
mitotic index and tumour size are non-linear continuous 
variables, so that the risk thresholds, especially based on 
number of mitoses, need to be interpreted with care. A 
modification to the NIH criteria has been proposed that 
incorporates tumour site and additionally tumour rup-
ture, an important risk factor, [18] see Table 2. Prognostic 
contour maps have been generated through a number of 
series of GIST patients not treated with adjuvant therapy. 
These maps incorporate the mitotic index and tumour 
size as continuous non-linear variables, while tumour 
rupture is considered in addition to tumour site. They 
have been validated against pooled data from 10 series 
and 2560 patients from the literature [19]. Several nomo-
grams and web or mobile phone applications are avail-
able to enable rapid risk category calculations to be made, 
which may assist multidisciplinary planning of patient 
management.
Staging procedures
Staging procedures take into account the fact that most 
relapses affect the peritoneum and the liver. Contrast-
enhanced abdominal and pelvic CT scan is the inves-
tigation of choice for staging and follow-up. Magnetic 
resonance imaging (MRI) or contrast-enhanced ultra-
sound may be alternatives, especially in younger patients 
where exposure to radiation should be limited. MRI pro-
vides better preoperative staging information for rectal 
GISTs. Chest CT scan or X-ray and routine laboratory 
testing complement the staging work-up of the asymp-
tomatic patient, but are not routinely required during 
follow-up. Evaluation of 18F-fluorodeoxyglucose (FDG) 
uptake using an FDG-positron emission tomography 
(PET) scan, or FDG-PET–CT/MRI, can sometimes be 
useful, mainly when early assessment of response to 
tyrosine kinase inhibitor therapy is of special interest, for 
example after initiation of neo-adjuvant imatinib therapy.
Treatment
When small oesophago-gastric or duodenal nodules 
less than 2  cm in size are detected, endoscopic biopsy 
may be difficult and laparoscopic/laparotomic exci-
sion may be the only way to make a histological diagno-
sis. Many of these small nodules, if diagnosed as GIST, 
will be low risk, or entities whose clinical significance 
remains unclear. Therefore, the standard approach to 
these patients is endoscopic ultrasound assessment, usu-
ally with fine needle aspiration or core needle biopsy, 
then annual follow-up, reserving excision for patients 
whose tumour increases in size or becomes symptomatic. 
Alternatively, the decision about a treatment plan can be 
discussed with the patient. This may depend on age, life 
expectancy and comorbidities. If follow-up is the choice, 
definitive evidence regarding an optimal surveillance pol-
icy is lacking, but annual follow-up is reasonable. For a 
small histologically proven GIST of 2 cm or greater, the 
standard treatment is excision, unless major morbidity 
is expected. Alternatively, in the case of a low-risk GIST, 
the possibility of surveillance could be discussed with the 
patient. Rectal (or recto-vaginal space) nodules should be 
biopsied and preferably excised after ultrasound assess-
ment, regardless of tumour size. This is because GISTs at 
these sites have a higher risk of local recurrence after sur-
gery, and the local implications for surgery in relation to 
morbidity are more critical. In specific clinical contexts, 
if the tumour is small, a follow-up policy without surgery 
could be adopted, but such an approach should be dis-
cussed in detail with the patient.
Multidisciplinary treatment planning is needed. This 
should involve histopathologists, radiologists, surgeons, 
and oncologists, as well as gastroenterologists, nuclear 
medicine specialists and others, as applicable. Such 
teams are available in reference centres for sarcomas 
and GISTs, which treat a large number of GIST patients 
annually. Support staff, such as clinical nurse specialists, 
play a vital role and are not likely to be available, or have 
the appropriate expertise, outside specialist centres.
Localised disease—surgery
Standard treatment of localized GISTs is complete surgi-
cal excision of the lesion, with no dissection of clinically 
negative lymph nodes [III, A]. Surgery should be per-
formed by a sub speciality surgeon who is fully trained 
and experienced in radical anatomic site specific can-
cer surgery. When adjacent organs are involved, en bloc 
resection is recommended wherever possible. If laparo-
scopic excision is planned, the technique needs to follow 
Table 2 Modified NIH risk classification for primary GIST 
After Joensuu [18]
Risk category Tumour size 
(cm)
Mitotic index 
(per 50 HPFs)
Primary tumour 
site
Very low risk <2.0 ≤5 Any
Low risk 2.1–5.0 ≤5 Any
Intermediate 
risk
2.1–5.0 >5 Gastric
<5.0 6–10 Any
5.1–10.0 ≤5 Gastric
High risk Any Any Tumour rupture
>10 Any Any
>5.0 >5 Any
2.1-5.0 >5 Non gastric
5.1–10.0 ≤5 Non gastric
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the principles of oncological surgery [20] [III, A]. A lap-
aroscopic approach is clearly discouraged in patients 
with large tumours, because of the risk of tumour rup-
ture, which is associated with a very high risk of relapse. 
R0 excision is the goal (i.e., an excision whose margins 
are clear of tumour cells). When R0 surgery is likely to 
result in major functional sequelae, e.g. total gastrec-
tomy or abdomino-perineal resection of rectum, neo-
adjuvant imatinib should be regarded as standard therapy 
[21–24] [IV, A]. Treatment is given to reduce the size 
of the tumour and to limit subsequent surgical mor-
bidity. This may also be the case if surgery will be safer 
following cyto-reduction (e.g. the risk of bleeding and 
tumour rupture is likely to be decreased). After maxi-
mal tumour response, generally after 6–12 months, sur-
gery is performed. Prior mutational analysis is crucial to 
prevent patients with less sensitive or resistant tumours 
(e.g. PDGFRA D842  V mutations) from receiving ther-
apy with imatinib, and to allow appropriate dosing for 
patients with KIT exon 9 mutated tumours. Early tumour 
response assessment is mandatory, so that surgery is not 
delayed in the case of non-responding disease. Functional 
imaging, such as PET-CT, makes it possible to assess the 
tumour response very rapidly, within a few weeks. There 
are limited data to guide the physician on when to stop 
imatinib before surgery, but it can safely be stopped a few 
days, or even 1 day, before surgery and it can be resumed 
promptly when the patient has recovered from the acute 
effects of surgery.
If preoperative medical treatment has not helped or 
cannot be used, there should be a discussion with the 
patient about accepting a possible R1 resection with 
microscopically positive margins (i.e. excision mar-
gins containing tumour cells) [IV, B]. This may be more 
acceptable for low-risk lesions, with the lack of any for-
mal demonstration that R1 surgery is associated with 
worse overall survival [25]. If an unplanned R1 exci-
sion has already been carried out, re-excision may be an 
option, provided the original site of lesion can be found, 
and major functional sequelae are not foreseen.
Localised disease—adjuvant therapy
The risk of relapse following surgery can be substan-
tial, as defined by available risk classifications. Adjuvant 
treatment with imatinib for 3 years was associated with 
improved relapse-free and overall survival compared 
with 1 year of therapy in a randomized trial in high-risk 
patients [26]. Previously, a placebo-controlled trial dem-
onstrated that imatinib given for 1 year prolongs relapse-
free survival in localized GISTs larger than 3 cm with a 
macroscopically complete resection [27]. Therefore, adju-
vant therapy with imatinib for 3 years is standard treat-
ment for patients with a significant risk of relapse [I, A] 
and was approved by the National Institute for Care and 
Health Excellence (NICE) in their recent re-appraisal 
(https://www.nice.org.uk/guidance/ta326). Mutational 
analysis is critical to making a clinical decision regard-
ing adjuvant therapy. In fact, there is a consensus that 
PDGFRA D842  V-mutated GISTs should not be treated 
with any adjuvant therapy, given the lack of sensitivity of 
this genotype to imatinib both in  vitro and in  vivo [IV, 
A]. Given the data supporting the use of a higher dose of 
imatinib (800 mg daily) in the presence of an exon 9 KIT 
mutation in advanced GIST, clinicians might consider 
using this dose in the adjuvant setting for this genotype 
[28–31]. However, this is not supported by any controlled 
trial data in the adjuvant setting and use of the higher 
dose is not approved by NICE in the UK. There is con-
sensus on avoiding adjuvant treatment in NF-1 related 
GISTs, which are insensitive to imatinib in the advanced 
setting. On the other hand, a consensus is lacking among 
experts about whether KIT/PDGFRA wild-type SDH-
negative GIST should be treated with adjuvant therapy. 
This reflects their lower sensitivity to imatinib, as well as 
their peculiar natural history, which is often more indo-
lent; subgroup analyses of available randomized trials are 
too limited to provide sufficient evidence.
If there has been tumour rupture before or during sur-
gery, there will have been spillage of tumour cells into the 
peritoneal cavity, and therefore occult peritoneal disease 
can be assumed to exist. This puts the patient at a very 
high risk of peritoneal relapse. Therefore, these patients 
should be considered for adjuvant imatinib therapy. The 
optimal duration of treatment in these cases is unknown, 
given the uncertainty as to whether they should be 
viewed as essentially having metastatic disease, but 
should be at least 3 years, as for high risk resected GIST.
Key recommendations
1. GIST should be managed by an experienced multi-
disciplinary team.
2. Pre-operative imatinib should be considered for 
those large gastric or rectal primaries where immedi-
ate resection is likely to be morbid, e.g. total gastrec-
tomy or abdomino-perineal resection. In this situ-
ation mutational analysis is mandatory prior to the 
initiation of imatinib therapy.
3. Patients at high risk of recurrence or distant relapse 
should receive 3 years of adjuvant imatinib, provided 
their tumour is not likely to be resistant to therapy 
(PDGFRA exon 18 mutation D842V).
Metastatic disease—systemic treatment
In patients with inoperable and metastatic disease, 
imatinib is the standard treatment [32, 33] [III, A], includ-
ing patients who had previously received the drug as 
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adjuvant therapy without relapse during this treatment. 
This also applies to metastatic patients whose disease has 
been completely removed surgically, although surgery 
as a primary approach to metastatic GIST is not recom-
mended. The standard dose of imatinib is 400  mg daily 
[I, A]. However, data have shown that patients with KIT 
exon 9 mutations fare better in terms of progression-free 
survival (PFS) on a higher dose of 800 mg daily, which is 
therefore the standard treatment in this subgroup [31] 
[III, A], albeit not recommended by a NICE appraisal 
which only assessed dose escalation in the context of dis-
ease progression. A report on the long term follow-up of 
the European/Australasian clinical trial which compared 
400 mg with 800 mg imatinib in patients with advanced 
GIST has shown a survival advantage for the initial use 
of the 800 mg dose in those with exon 9 mutations in KIT 
(Casali P et al., in press) indicating a need to review this 
issue in the UK. Treatment should be continued indefi-
nitely, since treatment interruption is generally followed 
by relatively rapid tumour progression, even when lesions 
have previously been surgically excised [34] [II, B]. At 
the start of treatment the patient should be alerted to 
the importance of adherence to therapy, and of possible 
interactions with concomitant medications and foods. 
They should also be given guidance about the best ways 
to handle any possible side effects. Dose intensity should 
be maintained by effective management of side effects, 
and a rational policy of dose reductions and interruptions 
should be applied if there is excessive, persistent toxicity. 
Retrospective data suggest that suboptimal plasma levels 
of imatinib are associated with a worse outcome, though 
a correlation with outcome has not been established pro-
spectively [35]. A recent report confirmed that patients 
with imatinib trough levels of less than 760 ng/ml, taken 
after a minimum of 3 months’ treatment, which equates 
to steady state [36], had a worse outlook in terms of pro-
gression-free survival, which applied in the case of both 
gastric and small bowel GIST [37]. Aside from its poten-
tial use to tailor the imatinib dose, plasma level assess-
ment may be useful in the case of: (i) patients receiving 
concomitant medications that put them at a risk of major 
interactions; (ii) unexpected observed toxicities; (iii) 
progression on 400  mg. Dose adaptation according to 
inadequate imatinib trough level is being studied in the 
Netherlands, and is a standard approach in a number of 
institutions. However, the use of a higher dose of imatinib 
in patients with progressive disease is not approved by 
NICE.
Close monitoring of the tumour response should be 
carried out in the early phases of treatment. Follow-up 
should be continued throughout the treatment, since the 
risk of secondary progression persists over time. Com-
plete excision of residual metastatic disease has been 
shown to be related to a good prognosis, provided the 
patient is responding to imatinib, but whether this is due 
to surgery or to patient selection [38–40] has never been 
demonstrated prospectively. Conducting a randomised 
trial did not prove feasible; thus, at the present time sur-
gery can be discussed with the patient but not recom-
mended on the basis of a definitive proof of benefit [III, 
C]. Surgical excision of progressive disease is not recom-
mended, given the poor results in published series, but 
surgery of limited progression, such as the ‘nodule within 
a mass’, has been associated with a progression-free inter-
val in the same range as for second-line treatment with 
sunitinib. So, this may be a palliative option in the indi-
vidual patient with limited progression, while continuing 
imatinib [V, C]. Non-surgical procedures, such as radi-
ofrequency ablation of liver metastases may also be used. 
Prior to performing such interventions PET-CT can 
be useful to confirm the location of imatinib-resistant 
disease.
Dose escalation of imatinib to 800 mg in the case of a 
GIST with a KIT exon 9 mutation showing disease pro-
gression could be considered if the higher dose was not 
used initially, since the higher dose is significantly more 
effective in this setting [31]. Higher doses, though not 
necessarily 800 mg, could be useful if satisfactory plasma 
levels of imatinib are not being achieved, but the use of 
higher doses is not approved by NICE. The potential 
misinterpretation of the images produced by the com-
plex tumour response patterns to TKIs can lead to a false 
diagnosis of progression, which must be considered. 
Patient non-compliance and drug interactions with con-
comitant medications must also be ruled out as the pos-
sible cause of progression.
If there is confirmed progression, or rare intolerance 
to imatinib after all attempts to manage side effects have 
failed, the standard second-line treatment is the tyros-
ine kinase inhibitor (TKI) sunitinib [41] [I, B]. This drug 
was proven to be effective in terms of PFS using a regi-
men of 50  mg daily 4  weeks on/2  weeks off. Data have 
been published showing that continuous treatment with 
a lower daily dose of 37.5  mg is also effective and well 
tolerated, although no formal comparison has been per-
formed within a randomized clinical trial. This schedule 
can therefore be considered an alternative on an individ-
ualized basis [42] [III, B]. However, not all patients resist-
ant to imatinib respond to sunitinib particularly those 
with secondary mutations affecting the activation loop 
domain of KIT and the PDGFRA exon 18 D842V muta-
tion, which is always resistant.
A prospective placebo-controlled randomized trial 
demonstrated that regorafenib, at a dose of 160 mg daily 
on a 3  weeks on/1  week off schedule, significantly pro-
longed PFS in patients progressing after both imatinib 
Page 7 of 10Judson et al. Clin Sarcoma Res  (2017) 7:6 
and sunitinib [43]. Regorafenib is regarded as standard 
therapy for the third-line treatment of patients progress-
ing on or failing to respond to imatinib and sunitinib [I, 
B]. It is currently available in England via the National 
Cancer Drugs Fund and is also available in Scotland, 
Wales and Northern Ireland as standard 3rd line therapy. 
The key distinction between sunitinib and regorafenib, 
as also previously shown with the analogue sorafenib, is 
its ability to inhibit tumours with secondary mutations in 
the activation loop of KIT, especially in exon 17 [44, 45]. 
These mutations are known to confer resistance both to 
imatinib and sunitinib, hence the value of regorafenib in 
this setting.
Patients with metastatic GIST failing all three standard 
agents should be considered for participation in clinical 
trials of new agents. These studies are only likely to be 
available in major centres treating GIST. There is limited 
evidence that patients who have already progressed on 
imatinib may benefit for a limited period when re-chal-
lenged with the drug [46]. Likewise, there is anecdotal 
evidence that maintaining treatment with a TKI even in 
the case of progressive disease, as opposed to stopping it, 
may slow down progression if no other option is available 
at the time. Therefore, re-challenging or continuing treat-
ment with a TKI, to which the patient has already been 
exposed, is an option which may be considered for symp-
tom control in patients with progression [V, B].
Metastatic disease—local therapy
Selected patients with limited liver metastatic disease 
may be amenable to surgery or radiofrequency ablation 
(RFA) after maximum response to imatinib, or if there is 
evidence of localised disease progression. The use of RFA 
is restricted to tumours in the region of 3  cm in maxi-
mum diameter and is less likely to be a suitable approach 
for lesions adjacent to large vessels or superficial lesions, 
especially if displacing the liver capsule. However, larger 
isolated lesions and superficial lesions may still be suit-
able for surgical resection, either by partial hepatectomy 
or wedge resection. Dedicated liver MRI scans and when 
appropriate PET-CT scans may be required to determine 
whether this is a legitimate approach by excluding other 
occult active disease.
Radiotherapy can be a useful local therapy in GIST 
under certain circumstances in the advanced disease set-
ting. If there is a single site of disease that is progressing 
on a TKI and can be encompassed within a radiotherapy 
treatment field, then radiotherapy delivered to a moder-
ate or high dose can offer local tumour control, and pos-
sibly prolong the use of the TKI [47]. Radiotherapy can 
also be used at lower doses to palliate symptomatic dis-
ease, for example to relieve pain or bleeding.
Response assessment
Response assessment is complex and early progression 
in particular should be confirmed by a team experienced 
in treating GIST. Anti-tumour activity translates into 
tumour shrinkage in most patients, but some patients 
may show only changes in tumour “density” on imaging, 
these changes sometimes precede a reduction in tumour 
volume. Such changes in tumour radiological appearance 
should be considered as indicative of tumour response. 
Tumour size may even increase in the short term but if 
tumour density on CT scan is decreased this may still 
indicate tumour response [48, 49]. Even the apparent 
‘appearance’ of new lesions may be due to them becom-
ing less dense, or cystic, especially in the liver. Therefore, 
both tumour size and tumour density on CT scan, or 
consistent changes on MRI or contrast-enhanced ultra-
sound, should be considered when determining tumour 
response. 18F-FDG-PET has proved useful in the early 
assessment of tumour response, for example when pre-
diction of the response is valuable, for example in the case 
of preoperative therapy, or when response is in doubt. 
However, a small proportion of GISTs have no FDG 
uptake. The absence of tumour progression at 6 months 
[50] is also equivalent to a tumour response. Conversely, 
tumour progression may not always be accompanied by 
changes in tumour size. For example, an increase in the 
tumour density shown by contrast enhancement within a 
previously responding low density tumour lesion, may be 
indicative of tumour progression. A typical progression 
pattern is the ‘nodule within the mass’, in which a portion 
of a responding lesion becomes hyper-dense [51].
Key recommendations
1. Imatinib is the treatment of choice for patients with 
unresectable or metastatic disease and is given until 
progression at the standard dose of 400  mg daily. 
Data suggest that patients whose tumours have an 
exon 9 mutation in KIT benefit from a larger dose, 
though this is not currently recommended by NICE.
2. Isolated progression may be amenable to surgery or 
other local measures, such as radiofrequency abla-
tion.
3. Standard second line treatment is sunitinib, which 
may be given at the recommended dose of 50  mg 
daily for 4 weeks every 6 weeks, or 37.5 mg daily con-
tinuously.
4. Standard 3rd line treatment is regorafenib.
Follow‑up
The optimal follow-up policy for surgically treated 
patients with localized disease is unclear. Relapses occur 
most often in the liver and/or the peritoneal cavity. 
Other sites of metastases, including bone and brain are 
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uncommon, but may be less unusual following prolonged 
treatment with several lines of therapy. The mitotic rate 
most likely affects the frequency with which relapses 
occur. Risk assessment based on the mitotic count, 
tumour size and tumour site may be useful in choosing 
the routine follow-up policy. High-risk patients generally 
relapse within 1–3 years from the end of adjuvant ther-
apy. Low-risk patients may relapse later, given that the 
disease is likely to be slower growing.
The issue of follow-up has been addressed by Joen-
suu and colleagues based on the currently available 
evidence [52]. High-risk patients who have undergone 
resection of their primary generally undergo a rou-
tine follow-up with abdominal CT or MRI scan every 
3–6  months during adjuvant therapy, for 3  years. This 
frequency of follow up is because of the need to man-
age the side effects of the therapy. On cessation of adju-
vant therapy follow up is every 3  months for 2  years, 
then every 6  months for another 3  years, after which 
follow up is annually for another 5 years. Patients with 
high-risk tumours not given adjuvant therapy, for 
whatever reason, should be followed up 3 monthly for 
2 years, 6 monthly for 3 years and then annually for a 
further 5 years.
For low to intermediate risk tumours, the optimal 
frequency of follow-up is less clear. If follow-up is per-
formed, it will usually be an abdominal CT or MRI scan, 
or ultrasound, every 6–12 months for 5 years.
Very low-risk GISTs do not require routine follow-up, 
provided excision was complete, although one must be 
aware that the risk of progression is not zero.
Radiation exposure is a factor to consider when select-
ing the imaging modality for long term follow-up. 
Abdominal MRI is an acceptable alternative to CT which 
could be used at selected intervals.
Key recommendations
1. Patients with high risk disease on adjuvant therapy 
should be followed up by cross-sectional imaging 
every 3–6 months during their 3 years of treatment, 
3 monthly for 2  years following cessation of treat-
ment and thereafter every 6 months for 3 years and 
annually for 5 years.
2. Patients with high risk disease not receiving adjuvant 
treatment should follow the post-adjuvant treatment 
scheme.
3. For patients with lesser levels of risk less frequent fol-
low-up is generally recommended, although the clini-
cal benefits are unclear. For intermediate risk patients 
6 monthly scans for 5 years followed by annual scans 
and for low risk patients shorter duration follow-up 
would be considered reasonable.
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